Treatment
Dinutuximab clinical trials
We’re tracking 15 recruiting studies that include Dinutuximab, each written for real people, not researchers, below.
Recruiting studies
- NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT04211675RecruitingPhase 1/Phase 2
Test NK cell infusions with irinotecan, temozolomide, and dinutuximab
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Columbus, OhioAges Up to 29 years - NCT06485947RecruitingPhase 1
Study testing dinutuximab beta with chemotherapy for neuroblastoma
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Utrecht, UtrechtAges 1.5 years–18 years - NCT07318831RecruitingPhase 2
Combination drug therapy for relapsed neuroblastoma
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Tianjin, Tianjin MunicipalityAges Any age - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years - NCT04253015Recruiting
Safety registry for people with high-risk neuroblastoma on dinutuximab beta
This study is a long-term safety and follow-up registry. It tracks how dinutuximab beta is doing in real-world patients with high-risk neuroblastoma over time.
Vienna, State of ViennaAges 1–18 - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT06450041RecruitingPhase 2
STING trial for high-risk neuroblastoma
This trial tests a combination of chemotherapy (temozolomide and irinotecan), natural killer cells (NK cells), and an antibody therapy (GD2 mAb) to see if it can help children and young adults with high-risk neuroblastoma that has not responded to treatment or has come back.
Los Angeles, CaliforniaAges 1–31 - NCT06669013RecruitingPhase 3
Chemo-immunotherapy for young people with bone or soft tissue sarcoma
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
Saint PetersburgAges Up to 18 years - NCT06995872RecruitingPhase 1
Study of rhIL-15 with immunotherapy and chemo for neuroblastoma
This trial tests a new combination of drugs (rhIL-15, dinutuximab, irinotecan, and temozolomide) for children and young adults whose neuroblastoma has come back or hasn't responded to other treatments. The goal is to see if this mix can help shrink or control the cancer.
Bethesda, MarylandAges 3–35 - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+
What Dinutuximab is being studied for
Conditions with recruiting Dinutuximab studies.
Common questions
- Are there clinical trials studying Dinutuximab?
- Yes. Clin2 currently lists 15 recruiting studies that include Dinutuximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dinutuximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dinutuximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dinutuximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.